Changeflow GovPing Pharma & Drug Safety GlaxoSmithKline Biopharmaceutical Composition P...
Routine Notice Added Final

GlaxoSmithKline Biopharmaceutical Composition Patent Application EP3630824A1

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The EPO Patent Bulletin published GlaxoSmithKline Intellectual Property Development Limited's patent application EP3630824A1 for biopharmaceutical compositions and related methods. The application covers immunological disorders (A61K 39/00, A61K 39/395, C07K 16/24), respiratory conditions (A61P 11/00, A61P 11/06), and dermatological applications (A61P 17/00). The application designates 33 European and international states including all EU member states, CH, TR, NO, and others.

What changed

The EPO Patent Bulletin published application EP3630824A1 filed by GlaxoSmithKline for biopharmaceutical compositions and methods. The application claims compositions for treating immunological disorders, respiratory conditions (asthma, COPD), and skin disorders using antibody-based therapies (C07K 16/24). The international patent classification includes A61K 39/00, A61P 11/00, A61P 17/00.\n\nPharmaceutical companies and biotech firms developing biological therapies should review the published claims for potential freedom-to-operate implications or licensing opportunities. The application has been published but not yet granted; interested parties may monitor EPO register for search reports and subsequent examination proceedings.

What to do next

  1. Monitor EPO register for further proceedings on application EP3630824A1

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS

Publication EP3630824A1 Kind: A1 Apr 08, 2026

Applicants

GlaxoSmithKline Intellectual Property Development
Limited

Inventors

GRANT, Steven, AKINSEYE, Chika, BHINDER, Tejinder, HOOK, Laura, LEWIS, Alan Peter, ORECCHIA, Martin

IPC Classifications

A61K 39/00 20060101AFI20251017BHEP A61P 11/00 20060101ALI20251017BHEP A61P 17/00 20060101ALI20251017BHEP A61P 11/06 20060101ALI20251017BHEP A61K 39/395 20060101ALI20251017BHEP C07K 16/24 20060101ALI20251017BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3630824A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing IP protection Biopharmaceutical development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!